Mizutani T, Mizutani H, Hashimoto K, Nakamura Y, Kishida M, Taniguchi H, Murata M, Kuzuhara S, Shimizu M
Department of Dermatology, Mie University, School of Medicine, Japan.
J Am Acad Dermatol. 1991 Sep;25(3):512-7. doi: 10.1016/0190-9622(91)70232-q.
A newly recognized and well-described connective tissue disease, eosinophilia-myalgia syndrome, is thought to relate to L-tryptophan ingestion. The suspect L-tryptophan made in Japan has been distributed in Japan and in the United States. Different from many case reports of eosinophilia-myalgia syndrome in the United States, it has not been reported in Japan. We describe the first case reports of two Japanese patients. Eosinophilia-myalgia syndrome developed in these patients simultaneously, during L-tryptophan treatment by the same physician using the same lot of prescribed L-tryptophan. Furthermore, both patients had the following HLA types: HLA-Aw33(w19), -B44(12), and -DR6. These findings implicate the existence of another factor in the development of eosinophilia-myalgia syndrome in addition to the suspect L-tryptophan.
嗜酸性粒细胞增多性肌痛综合征是一种新认识且已被充分描述的结缔组织病，被认为与摄入L-色氨酸有关。在日本生产的可疑L-色氨酸已在日本和美国销售。与美国许多嗜酸性粒细胞增多性肌痛综合征的病例报告不同，日本尚未有相关报告。我们描述了两例日本患者的首例病例报告。这两名患者在同一位医生使用同一批次处方L-色氨酸进行治疗期间，同时患上了嗜酸性粒细胞增多性肌痛综合征。此外，两名患者均具有以下HLA类型：HLA-Aw33（w19）、-B44（12）和-DR6。这些发现表明，除了可疑的L-色氨酸外，嗜酸性粒细胞增多性肌痛综合征的发病还存在其他因素。
